Talon Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

TLON 0.156
price chart
Spectrum Acquires Talon - A Takeunder Case Study
Spectrum Pharmaceuticals (NASDAQ:SPPI) is acquiring Talon Therapeutics (OTC:TLON) in a deal for $11.3 million cash plus contingent value rights (CVRs)worth "up to $195 million".
Spectrum Pharmaceuticals Acquires Talon Therapeutics  GlobeNewswire (press release)
Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc. For $195 Million  Benzinga
Related articles »  
Talon Therapeutics Looks Undervalued Following FDA Approval
Shareholders of Talon Therapeutics (OTC: TLON) saw a pleasant surprise on August 9th when the FDA approved the company's flagship product, Marqibo, three days earlier than expected. The initial decision date under the PDUFA was on August 12th, ...
Related articles »  
Talon Therapeutics Announces $11M Financing
SAN MATEO, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management, its largest shareholders, for the sale of ...
Related articles »  
Talon Therapeutics, Inc. (OTC:TLON) Falls Down on an Investor Update
Talon Therapeutics, Inc. (OTC:TLON, TLON message board) stock lost a large portion of its value in just two trading sessions last week.
Talon Therapeutics, Inc. (OTC:TLON) Jumps Out of the Trading Range
Yesterday, Talon Therapeutics, Inc. (OTC:TLON, TLON message board) jumped out of its trading range and got higher than usual trading activity.
Talon Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Good day ladies and gentlemen and welcome to the Talon Therapeutics 2012 Earnings Call and Business Update. At this time, all lines are in a listen-only mode.
Related articles »  
Talon Therapeutics Submits New Drug Application for Marqibo(R)
SAN MATEO, Calif., July 18, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced its New Drug Application (NDA) for Marqibo (vincristine sulfate liposomes injection) was submitted to the U.S.
Related articles »  
Talon Therapeutics wins approval for leukemia drug
The generally accepted notion in the drug-development space is that it takes $1 billion or more and 10-plus years to bring a therapeutic to market.
Talon Wins U.S. FDA Approval for Blood Cancer Treatment  Bloomberg
FDA approves Marqibo to treat rare type of leukemia  FDA.gov
Related articles »  
Hana Biosciences To Change Name To Talon Therapeutics
1, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, announced that its board of directors has approved changing its name to Talon Therapeutics, Inc. The ...
Related articles »  
New Patent Issued for Talon Therapeutics' Marqibo(R) Expands Disease ...
SOUTH SAN FRANCISCO, Calif., March 10, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON), today announced the issuance of U.S.
Related articles »